{"title":"18F-flurpiridaz PET成像的临床前景预示着冠状动脉疾病诊断和治疗的新前沿","authors":"René R. Sevag Packard","doi":"10.1038/s44161-024-00587-w","DOIUrl":null,"url":null,"abstract":"The PET radiotracer 18F-flurpiridaz has undergone rigorous clinical testing and gained FDA approval for the evaluation of coronary artery disease. Its unique properties suggest 18F-flurpiridaz has the potential to transform the field of nuclear myocardial perfusion imaging and blood flow quantification, with far-reaching effects on cardiovascular care.","PeriodicalId":74245,"journal":{"name":"Nature cardiovascular research","volume":"4 1","pages":"1-4"},"PeriodicalIF":9.4000,"publicationDate":"2025-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The clinical promise of 18F-flurpiridaz PET imaging heralds a new frontier in the diagnosis and management of coronary artery disease\",\"authors\":\"René R. Sevag Packard\",\"doi\":\"10.1038/s44161-024-00587-w\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The PET radiotracer 18F-flurpiridaz has undergone rigorous clinical testing and gained FDA approval for the evaluation of coronary artery disease. Its unique properties suggest 18F-flurpiridaz has the potential to transform the field of nuclear myocardial perfusion imaging and blood flow quantification, with far-reaching effects on cardiovascular care.\",\"PeriodicalId\":74245,\"journal\":{\"name\":\"Nature cardiovascular research\",\"volume\":\"4 1\",\"pages\":\"1-4\"},\"PeriodicalIF\":9.4000,\"publicationDate\":\"2025-01-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature cardiovascular research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.nature.com/articles/s44161-024-00587-w\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature cardiovascular research","FirstCategoryId":"1085","ListUrlMain":"https://www.nature.com/articles/s44161-024-00587-w","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
The clinical promise of 18F-flurpiridaz PET imaging heralds a new frontier in the diagnosis and management of coronary artery disease
The PET radiotracer 18F-flurpiridaz has undergone rigorous clinical testing and gained FDA approval for the evaluation of coronary artery disease. Its unique properties suggest 18F-flurpiridaz has the potential to transform the field of nuclear myocardial perfusion imaging and blood flow quantification, with far-reaching effects on cardiovascular care.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
